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Abstract  
Objective and design: The renal expression of H1 and H2 receptors was previously demonstrated, while that of the H4 
receptor has been poorly investigated, thus the aim of this research was to investigate the expression of the H4 receptor 
in the kidney of diabetic rats. 
Material or subjects: 24 8-week-old male Wistar rats 
Treatment: Diabetes was induced in 12 rats by a single i.v. injection of streptozotocin, and animals were sacrificed 6 
weeks later. 
Methods: Kidneys were collected and processed for quantitative PCR or immunohistochemical analyses. To ascertain 
the renal topology of the H4 receptor, colocalization experiments were performed with a series of markers.  
Results: H4 receptor is expressed in healthy rats, although at a very low level, and is profoundly upregulated in diabetic 
animals. Immunohistochemical analysis revealed the highest immune-positivity in the medulla. Colocalization 
experiments revealed a close overlap in expression topology of the H4 receptor and both Tamm-Horsfall glycoprotein 
and aquaporin 1 was observed. 
Conclusions: The results demonstrate, for the first time, that the H4 receptor is expressed in the kidney mainly by 
resident renal cells of the loop of Henlé and that this receptor is significantly overexpressed in diabetic animals, thus 
suggesting a possible role in the pathogenesis of diabetes-associated renal disease.  
 
Keywords Histamine, histamine H4 receptor, diabetes, kidney, loop of Henlé 
 
 
 
4 
Histamine is a biogenic amine that exerts many (patho)physiological effects through its interaction with four subtypes 
of G-protein-coupled receptors, designated H1-4, which are differentially expressed in various tissues and cell types. It is 
synthesized from L-histidine through the catalytic activity of the rate-limiting enzyme histidine decarboxylase (HDC). 
Although HDC is principally expressed in mast cells, the most important source of histamine, it is well recognized that 
a number of other cell types, such as tuberomammillary nucleus (TMN) neurons in the brain and parietal cells in the 
stomach [1], also express this enzyme. Notably, HDC expression has been also reported in the kidney, where it was 
found in the proximal tubule [2], thus in keeping with the demonstrated ability of the kidney to produce histamine. 
In particular, in humans the renal histamine content markedly exceeds plasma levels (<10-8 M in plasma vs ≈10-6 M in 
glomeruli) [3]. Indirect demonstrations sustain the hypothesis that histamine could be involved in renal pathophysiology 
in humans. In fact, it was demonstrated in healthy subjects that loading doses of L-histidine led to an increase in 
histamine concentration in urine, but not in blood [4], and that urinary and blood levels of histamine are elevated 
following renal transplantation [5].  
Some studies suggest that histamine may be involved in diabetes-related kidney disease. Studies performed in 
streptozotocin (STZ) diabetic rats have shown, consistently with a generalized effect of diabetes on inducing an increase 
in histamine, a greater content of histamine in the kidney of diabetic animals than that of controls [6, 7]. This increase 
has been related to a significantly greater tissue HDC activity of diabetic rats than controls without a concomitant 
decrease in histaminase activity [8], an enzyme that catalyzes the inactivation of histamine. Besides, it has been 
suggested that renal histamine may represent one triggering stimulus for the functional microangiopathy in diabetes 
mellitus, which may lead to the development of diabetic nephropathy. In fact, it has been reported, in rats, that 
histamine reduces the ultrafiltration coefficient [9]. These data are in keeping with more recent studies aimed to assess 
the role of mast cells in the kidney. It is well recognized that in the normal kidney, mast cells are constitutively present 
at low numbers. However, their density and activation increase in the renal cortical tubulointerstitium and in the 
periglomerular and perivascular area, but not in glomeruli, in a variety of human renal diseases, including diabetic 
nephropathy [10-12].  
Hitherto, the renal effects of histamine have been related to the activation of H1 and H2 receptor, both identified in the 
glomeruli [3, 13], while the H4 receptor expression in the kidney was poorly investigated. A very low level of H4 
receptor mRNA has been reported in the kidney of dog, monkey, rat, mouse, guinea pig and pig [14-18]. Despite the 
demonstration of an increasing histamine release in diabetic kidney, there is no evidence for the involvement of H4 
receptor expression in the diabetes-related kidney disease. Thus, in order to gain further insight into the histamine signal 
in the diabetic kidney, the aim of this pilot study was to investigate the expression of the H4 receptors in the kidney of 
diabetic rats with severe hyperglycemia. 
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Materials and methods 
Animals and protocols 
Male 8-week-old Wistar rats (Harlan–Italy, Udine, Italy) were provided with a Piccioni pellet diet (No. 48; Gessate 
Milanese, Italy) and water ad libitum. Animal care was in compliance with Italian regulations on the protection of 
animals used for experimental and other scientific purposes (D.M. 116/92). The experimental protocol was approved by 
the Turin University Ethics Committee for the animal use.  
Diabetes induction 
Insulinopenic diabetes was induced by a single intravenous tail vein injection of streptozotocin (STZ; 50 mg/kg) diluted 
in citrate buffer 0.1 M (pH 4.0) in accordance to the literature (Wu and Huan, 2008). Rats were randomised into two 
groups: (1) non-diabetic animals (n = 12) and (2) diabetic animals (n = 12). A blood sample was collected 4 days after 
the STZ injection, and plasma glucose was determined using a glucose analyzer (Accu-Chek Compact System; Roche 
Diagnostics, Basel, Switzerland). Diabetes was defined by a blood glucose level of > 300 mg/dl. Six weeks after 
induction of diabetes, when experimental rats reached a blood glucose level > 300 mg/dl (severe hyperglycemia), 
rodents were weighed and placed in metabolism cages to collect 24 h urine. Animals were killed after aortic 
exsanguination under anaesthesia by ip injection (30 mg/kg) of Zoletil 100 (15 mg/kg tiletamine + 15 mg/kg 
zolazepam; 100 mg/ml; Laboratoires Virbac, France). Blood samples were stored at −80°C. Kidneys were isolated, 
weighed and processed for biochemical or histological evaluation according to standard procedures by rapidly freeze-
clamping with liquid nitrogen and stored at −80 °C or fixing in 4% paraformaldehyde solution overnight, respectively. 
Measurement of biochemical and histological parameters 
Serum and urine creatinine concentrations were measured spectrophotometrically at 490 nm by the Jaffé kinetic 
reaction (Schlatzer et al., 2009), using commercially available kits (Cat. Nos. KB02-H1, K002-H1; DetectX, Arbor 
Assays, MI, USA). Renal creatinine clearance was calculated by the standard formula C = (U × V) / P, where U is the 
concentration in urine, V is urine flow rate, and P is the plasma concentration. Creatinine concentrations and creatinine 
clearance were used as indicators of impaired renal function, whereas N-Acetyl-β-glucosaminidase (NAG), measured in 
the urine by a colorimetric assay (Roche Diagnostics), was used as a marker of tubular injury [19]. 
Histological sections, 5 µm thick, were cut from the paraffin-embedded kidney samples. Tissue sections were stained 
with periodic acid-Schiff (PAS) in a single session to minimize artifactual differences in the staining. Photomicrographs 
of the histological slides were randomly taken with a digital camera connected to a light microscope equipped with a 
x40 objective. In total, 10 images and 60 glomeruli from each rat were examined by two independent investigators 
blinded to the experimental group. 
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RT-PCR and quantitative real-time PCR analysis 
The analyses were performed as previously described [20]. Briefly, RT-PCR amplifications were performed in 25µl 
reaction mixtures containing 1.0 µl of cDNA, 2.5 µl of 10× buffer, 1.0 µl of 50 mM MgCl2, 0.20 µl of 25 mM dNTPs 
mix, 0.05 U of EuroTaq DNA polymerase (Euroclone, Milan, Italy), and 2.5 nM of sequence-specific oligonucleotide 
primers (Sigma-Genosys, Milan Italy): H4R (147 bp) forward 5'-TGCCAGCTTCTGTCTCTGTC-3', reverse 5'-
ACTGCTGTTGGCTCGTGTTC-3'; 18S (489 bp) forward 5′-TCAAGAACGAAAGTCGAAGGT-3′, reverse 5′-
GGACATCTAAGGGCATCACAG-3′. PCR amplicons were resolved in an ethidium bromide-stained agarose gel (3%) 
by electrophoresis, and signals were quantified using NIH ImageJ 1.41 software. 18S gene expression was used as an 
internal control. Real-time PCR experiments were performed in 25 µl reaction mixtures containing 10 ng of cDNA 
template, Power SYBR® Green PCR Master Mix and AmpliTaq Gold® DNA Polymerase LD (Applied Biosystems, 
Inc., Foster City, CA, USA), was directed to detect and quantify H4 receptor mRNA. Relative quantification of the 
products was performed using a 48-well StepOne™ Real Time System (Applied Biosystems). For all real-time PCR 
analyses, 18S mRNA was used to normalize RNA inputs. 
Antibodies 
H4 receptor was detected by using the anti-hH4 receptor (374-390) antibodies produced and validated for detecting both 
human and rodent H4 receptors in the School of Biological and Biomedical Sciences, Durham University [21-27]. 
Briefly, the antibody was generated against the last 17 amino acids of the C-terminal tail of the H4 receptor conjugating 
the peptide corresponding to the amino acids CIKKQPLPSQHSRSVSS to thyroglobulin by the cysteine-coupling 
method [28]. The resultant conjugate was used to generate polyclonal antibodies in rabbits as previously described [29]. 
The selectivity of the anti-h H4 receptor antibody was confirmed by blockade with the C-terminal peptide of the H4 
receptor and a lack of cross reactivity with the human H3 receptor, the most related G-coupled receptor [26]. 
For comparison, a commercial available anti-H4 receptor (Y-19; sc-33967 Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) was also employed. The antibodies for renal markers, aquaporin (AQP)1, AQP2, Na-K-Cl cotransporter 
(NKCC)1, Tissue non-specific alkaline phosphatise (TNAP) and Tamm-Horsfall glycoprotein (THP), were purchased 
from Santa Cruz Biotechnology, Inc.; while the secondary biotinylated anti-rabbit and anti-goat antibodies were from 
Vector Laboratories, Inc. (Burlingame, CA, USA) and the secondary Alexa Fluor-488 anti-goat or Alexa Fluor-594 
anti-rabbit polyclonal antibodies were from Molecular Probes (Leiden, the Netherlands). 
Immunohistochemistry 
Conventional immunohistochemical procedures were employed as described previously [30, 31]. Briefly, 
immunoperoxidase staining for H4 receptor, AQP1, AQP2, NKCC1, TNAP and THP, was performed on 5 µm sections 
for formalin-fixed tissue using an appropriate antigen retrieval (sodium citrate 50 mM pH 8.4 for 30 min at room 
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temperature followed by sodium citrate 50 mM pH 8.4 for 30 min at 80°C for the anti-hH4 receptor (374-390); or 
sodium citrate 10 mM pH 6.9 for 3 cycles of 20 s in microwave 750 W for the anti-H4 receptor (Y-19)); sections were 
incubated overnight with anti-hH4 receptor (374-390) or anti-H4 receptor (Y-19) (2 µg/ml) or anti-AQP1, -AQP2, -
AQP3, -NKCC1, -TNAP and -THP (4 µg/ml) at 4°C, followed by a three-layer streptavidin–biotin–peroxidase complex 
staining method (Vectastain ABC Elite kit and 3',3-diaminobenzadine tetrahydrochloride, DAB; Vector Laboratories, 
Inc.). Tissue was also screened in the absence of primary antibody. In all cases, a major part of the staining elicited by 
the untreated antibody was abolished. All sections were stained or immunostained in a single session to minimize 
artifactual differences in the staining. Photomicrographs of the histological slides were randomly taken with a digital 
camera connected to a light microscope equipped with a ×40 objective (Leica DM750). 
Immunofluorescence and confocal analysis 
After antigen retrieval and blocking, 5 µm kidney paraffin sections were incubated with primary anti-H4 receptor and 
anti-THP or -AQP1 antibodies, followed by incubation with Alexa Fluor-488 anti-goat or Alexa Fluor-594 anti-rabbit 
polyclonal antibodies. After counterstaining with DAPI, photomicrographs were obtained by a confocal laser-scanning 
microscope LSM-510 microscope equipped with a ×40 objective (Carl Zeiss, Oberkochen, Germany). 
Image Analysis 
Images were processed by ImageJ 1.41 (NIH, USA) software and quantified using the Color Deconvolution image 
analysis tool as previously described [30-33]. Briefly, H4 staining defined by diaminobenzidine were colour 
deconvoluted from counter-stained sections. A threshold was chosen for identifying H4 positive staining areas and used 
on all slides in the study without modification. The percentage area was calculated for H4 positive tissue. Values are 
means ± S.E.M. of the OD (in arbitrary units) measurements of individual rats (ten images/zone each) from the different 
experimental groups. 
Data analysis 
Results are shown as means ± SEM and were analysed by Student's t-test or one-way ANOVA with Dunnett's multiple 
comparison and Student–Newman–Keuls tests were used to determine significant differences between means: p-values 
less than 0.05 were considered significant. Data analysis assumed normality, using Prism 4 software from Graphpad 
(CA, USA). 
 
Results 
Pathophysiology and renal histology 
As shown in Table 1, in comparison to controls, body weight was reduced and blood glucose level was increased in 
diabetic rats. The kidney-to-body weight ratio was significantly higher, thus suggesting an organ hypertrophy. The 
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creatinine clearance was significantly decreased. The increase in urinary NAG level suggested tubular dysfunction 
(Table 1). Consistently, these biochemical abnormalities were associated with clear changes in renal histology. Using 
PAS staining, histological analysis of kidney sections from the diabetic animals showed severe tubular alterations and 
moderate glomerular modifications. In fact, in comparison to controls, STZ-treated rats revealed interstitial space 
increase and marked tubular degeneration associated with robust tubular epithelial cells loss and decreased PAS 
positivity of the brush-border membranes (Figure 1a and 1b). Moreover, the glomeruli of diabetic rats displayed 
moderate capsular fibrosis and tuft-to-capsule adhesion, with capillary dilatation and mild mesangial matrix expansion 
(Figure 1c and 1d). 
Renal H4 receptor expression in diabetic rats 
In control rats the H4 receptor gene was constitutively expressed, although unevenly and at a very low level (Figure 2a). 
In contrast, a higher expression level was detected in STZ-treated animals (Figure 2b). The PCR data were confirmed 
by immunohistochemical analysis (Figure 3). In particular, while there was very weak H4 receptor-like 
immunoreactivity in control rats, a high level of labelled cells in both medulla and cortex of diabetic animals was 
observed. In contrast, in the papilla the immunoreactivity was generally very low. Interestingly, H4 receptor-like 
immunoreactivity was not detectable in the glomeruli. This observation was confirmed using a quantitative image 
analysis, performed with the Color Deconvolution image analysis tool. As shown in Figure 4 the calculated percent area 
for the H4 receptor-like immunoreactivity was significantly higher in the medulla, while the papilla showed modest 
DAB positivity. These results were obtained by using the anti-hH4 receptor (374-390) antibody. Comparable results 
were observed with the commercially available anti-H4 receptor (Y-19). The similar results validate the use of the anti-
hH4 receptor (374-390) antibody to detect the H4 receptor in the rat kidney. 
H4 receptor cellular localization 
The above data, indicating a higher H4 receptor-like immunoreactivity in the medulla, suggest a tubular expression of 
the receptor. Thus, we have performed sequential section staining with different tubular cells markers to distinguish 
between the different portions of the nephron. When H4 receptor immunostaining was compared to individual tubular 
cell markers, a close overlap in expression topology was suggested with the markers of the loop of Henlé (Online 
Resource 2). To confirm and refine this result immunoflorescence staining and confocal analysis was performed with 
both THP, marker of the thick ascending limb of the loop of Henlé, and AQP-1,  marker of both the proximal tubules, 
the thin descending limb of the loop of Henlé and also expressed on some walls of microvessels. As shown in Figure 5, 
H4 receptor colocalizes with both THP and AQP1 proteins, and it is mainly expressed at the apical membrane of the 
epithelial cells. These results suggest that the H4 receptor is mainly expressed by resident renal cells of the loop of 
Henlé. 
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Discussion 
Our results demonstrate for the first time that the H4 histamine receptor is mainly expressed by cells of the loop of 
Henlé, and that this protein is significantly upregulated in the kidneys of diabetic animals, hence suggesting a possible 
role of the H4 receptor in the pathogenesis of diabetes-associated renal disease. 
Herein, we have reported the immunohistochemical identification the H4 receptor in the kidney. The first observation of 
renal H4 receptor expression dates back to its discovery in 2000 [18, 34-39]. In particular, RT-PCR experiments 
demonstrated the renal expression of the gene encoding for the H4 receptor [36]. These data were not confirmed by 
Northern blot analysis, so it has been postulated that the H4 receptor could be expressed by a minor cell population. 
Later, the constitutive, but very low H4 receptor gene expression, was confirmed in different species [14-18, 36]; 
however, all these studies did not provide for the topological evaluation and cell type identification of the receptor. In 
contrast, our work was directed to assess the intra-renal distribution and levels of H4 receptor. Consistently with 
previous studies, we measured, in control rats, H4 receptor mRNA at the lower limit of detectability. This very low 
expression is in keeping with the weak positivity when immunoistochemistry evaluation was performed. Importantly, 
we observed that all diabetic animals with overt hyperglycemia (6 weeks after induction of diabetes), although did not 
meet the criteria for diabetic nephropathy, showed renal damage and expressed profoundly higher levels of H4 
receptors, thus suggesting a strong association between diabetes-associated renal damage and H4 receptor 
overexpression. However, the present pilot study was only observational, and future work will focus on the functional 
consequences of the elevated levels of H4 receptor and the respective regulatory mechanisms. 
Previously, it has been shown that diabetic animals have a higher intra-renal histaminergic level [6, 7]. Moreover, 
parallel to the enhanced HDC enzyme activity [8], an increase in number and degranulation of mast cells was also 
demonstrated in the diabetic kidney [10-12]. The resulting higher histamine renal content was previously linked to the 
microvascular diabetes-associated changes in the glomerulus, where the expression of only H1 and H2 receptors was 
demonstrated [3, 13, 40]. However, all these studies were initiated prior to the discovery of the H3 and H4 receptors and 
were based on pharmacological characterization performed using dimaprit. This compound was initially characterized 
as a selective H2 receptor agonist, but nowadays it has been found to act also on the H4 receptor subtype, but with a 
much higher affinity [41]. Thus, these data suggest that a possible role of the H4 receptor in mediating the renal effect of 
histamine could not be ruled out. Moreover, the discovery of H1 and H2 receptors only in the glomerulus led researchers 
to discard the hypothesis of a potential role for histamine in the tubules. Our findings, which demonstrate that the H4 
receptor subtype is absent in the glomeruli, but present in the tubules, leads us to revisit a tubular effect for histamine. 
This idea is in keeping with the presence of mast cells, not only in the periglomerular and perivascular area, but also in 
the tubulointerstitium and, occasionally, in the wall of atrophied tubules [12]. Thus, a possible role of histamine 
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released by mast cells and of the H4 receptor in the tubular interstitium in promoting renal inflammation and fibrosis 
[11, 12] would be an intriguing hypothesis. Notably, the H4 receptor is exquisitely sensitive to local histamine levels 
[42]. 
Another original contribution of our study is to provide an intra-nephron localization of the H4 receptor. Colocalization 
experiments revealed that the H4 receptor is expressed at the apical membrane of AQP1- and THP-positive cells, which 
are identified as epithelial cells of the loop of Henlé. This cellular localization suggests a possible role of the H4 
receptor distinct from the regulation of immune responses and inflammatory cell recruitment [43], leading us to 
hypothesize an active role of this receptor in modulating the loop of Henlé function(s), such as the transmembrane 
soluble transport processes. This study adds to the growing list of cell types expressing the H4 receptor, subserving 
putative distinct roles to the other histamine receptors in the body, the latter including exocrine and endocrine functions 
in salivary glands [44] and the GI tract [25], respectively. 
Collectively, these data provide compelling evidence for kidney H4 expression and an anatomical basis which strongly 
suggests that the H4 receptor could play a role in the onset/progression of diabetes-associated renal disease. 
Interestingly, although expression differences were observed among species [14, 15, 17, 18, 34], the similar tissue 
distribution in different mammals indicates conserved and comparable physiological roles of the H4 receptor across 
species. Therefore, we could speculate similar roles in humans. On this basis, it is possible to hypothesize that our data 
on diabetic rats could have a positive translation to diabetic patients. However, whether this receptor has a 
compensatory or pathological implication remains to be established. In particular, understanding which effects an 
activation of H4 receptor could exert on the loop of Henlé function is still to be resolved, and could represent the basis 
for proposing the renal H4 receptor as a new potential pharmacological target for treating diabetes-associated renal 
disease. 
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Title and legends 
Figure 1. Renal morphology assessed by PAS staining. Representative micrographs of kidney tissue from control rats 
(a, c) and diabetic animals (b, d). (a) Normal tubules. (b) Severe tubular degeneration with widespread epithelial cells 
loss, decreased PAS positivity of the brush-border membranes (arrows) and increased interstitial space (asterisks). (c) 
Normal glomerulus. (d) Glomerulus with capillary dilatation (arrowheads) and moderate mesangial matrix expansion 
(fibrillar and heterogeneous PAS-positive stained material). Original magnification 40X. 
 
Figure 2. H4 receptor expression: comparison between healthy and diabetic rats. (a) RT-PCR analysis of H4 
receptor kidney expression (12 rats/group). Pos= positive control (H4 minigene), neg= negative control (water); (b) 
Quantitative RT-PCR analysis of H4 receptor kidney expression. Data were normalized with 18S mRNA value. Results 
are the mean ± SEM for three independent experiments performed in duplicate. Data were analyzed by one-way 
analysis of variance (ANOVA) and the Student–Newman–Keuls test. *p < 0.01 vs control. 
 
Figure 3. H4 receptor expression: comparison between healthy and diabetic rats. Representative micrographs of 
transverse kidney sections, immunolabelled with specific anti-H4 receptor antibody. Original magnification 40X. 
 
Figure 4. Quantitative assessment of H4 receptor distribution in the kidney. Relative ratio of total H4 positive 
staining area/total area as determined by color deconvolution. Results are the mean ± SEM of the OD (arbitrary units) 
of individual rats (ten images/zone) performed in duplicate. Data were analyzed by one-way analysis of variance 
(ANOVA) and the Student–Newman–Keuls test. *p < 0.01 vs cortex and # p < 0.01 vs papilla. 
 
Figure 5. H4 receptor localization on the Loop of Henlé. Immunofluorescence stain showing colocalization of H4 
receptor with THP (a) and AQP1 (b) positive cells. Original magnification 40X. 
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